{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:33:24Z","timestamp":1790948004743,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Campbell University College of Pharmacy and Health Sciences"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Limited retrospective data suggest prophylactic oral vancomycin may prevent Clostridioides difficile infection (CDI). We sought to evaluate the effectiveness of oral vancomycin for the prevention of healthcare facility\u2013onset CDI (HCFO-CDI) in targeted patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a randomized, prospective, open-label study at Novant Health Forsyth Medical Center in Winston-Salem, North Carolina, between October 2018 and April 2019. Included patients were randomized 1:1 to either oral vancomycin (dosed at 125 mg once daily while receiving systemic antibiotics and continued for 5 days postcompletion of systemic antibiotics [OVP]) or no prophylaxis. The primary endpoint was incidence of HCFO-CDI. Secondary endpoints included incidence of community-onset healthcare facility\u2013associated CDI (CO-HCFA-CDI), incidence of vancomycin-resistant Enterococci (VRE) colonization after receiving OVP, adverse effects, and cost of OVP.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 100 patients were evaluated, 50 patients in each arm. Baseline and hospitalization characteristics were similar, except antibiotic exposure. No events of HCFO-CDI were noted in the OVP group compared with 6 (12%) in the no-prophylaxis group (P = .03). CO-HCFA-CDI was identified in 2 patients who were previously diagnosed with HCFO-CDI. No patients developed new VRE colonization, with only 1 patient reporting mild gastrointestinal side effects to OVP. A total of 600 doses of OVP were given during the study, with each patient receiving an average of 12 doses. Total acquisition cost of OVP was $1302, $26.04 per patient.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>OVP appears to protect against HCFO-CDI during in-patient stay in targeted patients during systemic antibiotic exposure. Further prospective investigation is warranted.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciz966","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:42:58Z","timestamp":1569544978000},"page":"1133-1139","source":"Crossref","is-referenced-by-count":53,"title":["Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility\u2013Onset Clostridioides difficile Infection in Targeted Patients During Systemic Antibiotic Exposure"],"prefix":"10.1093","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2150-5812","authenticated-orcid":false,"given":"Steven W","family":"Johnson","sequence":"first","affiliation":[{"name":"Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Science, Buies Creek, North Carolina, USA"},{"name":"Department of Pharmacy, Novant Health Forsyth Medical Center, Winston-Salem, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon V","family":"Brown","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Campbell University College of Pharmacy and Health Science, Buies Creek, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H","family":"Priest","sequence":"additional","affiliation":[{"name":"Novant Health Institute for Safety and Quality, Winston-Salem, North Carolina, USA"},{"name":"Novant Health Infectious Disease Specialists, Winston-Salem, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"2020082200570245300_CIT0001","author":"Centers for Disease Control and Prevention"},{"key":"2020082200570245300_CIT0002","doi-asserted-by":"crossref","first-page":"S88","DOI":"10.1093\/cid\/cis335","article-title":"Burden of Clostridium difficile on the healthcare system","volume":"55","author":"Dubberke","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0003","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1086\/502023","article-title":"Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals","volume":"23","author":"Miller","year":"2002","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020082200570245300_CIT0004","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1086\/519258","article-title":"Impact of a reduction in the use of high-risk antibiotics on the course of an epidemic of Clostridium difficile-associated disease caused by the hypervirulent NAP1\/027 strain","volume":"45","author":"Valiquette","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0005","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1086\/522654","article-title":"Control of an outbreak of infection with the hypervirulent Clostridium difficile BI strain in a university hospital using a comprehensive \u201cbundle\u201d approach","volume":"45","author":"Muto","year":"2007","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0006","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/jac\/dkm014","article-title":"Successful use of feedback to improve antibiotic prescribing and reduce Clostridium difficile infection: a controlled interrupted time series","volume":"59","author":"Fowler","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"2020082200570245300_CIT0007","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1086\/502278","article-title":"Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years","volume":"24","author":"Carling","year":"2003","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020082200570245300_CIT0008","doi-asserted-by":"crossref","first-page":"S43","DOI":"10.1086\/521861","article-title":"Measures to control and prevent Clostridium difficile infection","volume":"46","author":"Gerding","year":"2008","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0009","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S1473-3099(16)30514-X","article-title":"Effects of control interventions on Clostridium difficile infection in England: an observational study","volume":"17","author":"Dingle","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2020082200570245300_CIT0010","first-page":"CD006095","article-title":"Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children","author":"Goldenberg","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"2020082200570245300_CIT0011","doi-asserted-by":"crossref","first-page":"ofy192","DOI":"10.1093\/ofid\/ofy192","article-title":"No impact of probiotics to reduce Clostridium difficile infection in hospitalized patients: a real-world experience","volume":"5","author":"Box","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2020082200570245300_CIT0012","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/cix1085","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults and children: 2017 update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA)","volume":"66","author":"McDonald","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0013","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1093\/cid\/ciw401","article-title":"Efficacy of oral vancomycin in preventing recurrent Clostridium difficile infection in patients treated with systemic antimicrobial agents","volume":"63","author":"Van Hise","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0014","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1038\/ajg.2016.417","article-title":"Efficacy of secondary prophylaxis with vancomycin for preventing recurrent Clostridium difficile infections","volume":"111","author":"Carignan","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"2020082200570245300_CIT0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1060028017727756","article-title":"Vancomycin prophylaxis for prevention of Clostridium difficile infection recurrence in renal transplant patients","volume":"52","author":"Splinter","year":"2018","journal-title":"Ann Pharmacother"},{"key":"2020082200570245300_CIT0016","first-page":"897190019825994","article-title":"Long-term efficacy of oral vancomycin prophylaxis for the prevention of Clostridium difficile recurrence","volume":"11","author":"Knight","year":"2019","journal-title":"J Pharm Pract"},{"key":"2020082200570245300_CIT0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12879-019-3676-1","article-title":"Prolonged oral vancomycin for secondary prophylaxis of relapsing Clostridium difficile infection","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2020082200570245300_CIT0018","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1080\/23744235.2018.1425551","article-title":"Efficacy of oral vancomycin in primary prevention of Clostridium difficile infection in elderly patients treated with systemic antibiotic therapy","volume":"50","author":"Papic","year":"2018","journal-title":"Infect Dis (Lond)"},{"key":"2020082200570245300_CIT0019","article-title":"Oral vancomycin prophylaxis is highly effective in preventing Clostridium difficile infection in allogeneic hematopoietic cell transplant recipients","author":"Ganetsky","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0020","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1017\/ice.2019.88","article-title":"Oral vancomycin prophylaxis during systemic antibiotic exposure to prevent Clostridiodes difficile infection relapses","volume":"40","author":"Caroff","year":"2019","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2020082200570245300_CIT0021","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00090-08","article-title":"Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease","volume":"52","author":"Al-Nassir","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2020082200570245300_CIT0022","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/1471-2334-10-363","article-title":"Faecal pharmacokinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection","volume":"10","author":"Gonzales","year":"2010","journal-title":"BMC Infect Dis"},{"key":"2020082200570245300_CIT0023","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1093\/cid\/ciw424","article-title":"Editorial commentary: potential risks and rewards with prophylaxis for Clostridium difficile infection","volume":"63","author":"Johnson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0024","doi-asserted-by":"crossref","first-page":"e76269","DOI":"10.1371\/journal.pone.0076269","article-title":"Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole","volume":"8","author":"Abujamel","year":"2013","journal-title":"PLoS One"},{"key":"2020082200570245300_CIT0025","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/infdis\/jiv256","article-title":"Loss of microbiota-mediated colonization resistance to Clostridium difficile infection with oral vancomycin compared with metronidazole","volume":"212","author":"Lewis","year":"2015","journal-title":"J Infect Dis"},{"key":"2020082200570245300_CIT0026","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7326\/0003-4819-117-4-297","article-title":"Treatment of asymptomatic Clostridium difficile carriers (fecal excretors) with vancomycin or metronidazole. A randomized, placebo-controlled trial","volume":"117","author":"Johnson","year":"1992","journal-title":"Ann Intern Med"},{"key":"2020082200570245300_CIT0027","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.ajic.2018.08.021","article-title":"Development of a risk prediction model for hospital-onset Clostridium difficile infection in patients receiving systemic antibiotics","volume":"47","author":"Tilton","year":"2019","journal-title":"Am J Infect Control"},{"key":"2020082200570245300_CIT0028","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1093\/jac\/dkr508","article-title":"Time interval of increased risk for Clostridium difficile infection after exposure to antibiotics","volume":"67","author":"Hensgens","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2020082200570245300_CIT0029","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1093\/cid\/cis1209","article-title":"All-cause and disease-specific mortality in hospitalized patients with Clostridium difficile infection: a multicenter cohort study","volume":"56","author":"Hensgens","year":"2013","journal-title":"Clin Infect Dis"},{"key":"2020082200570245300_CIT0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.05.008","article-title":"Risk factors for mortality in Clostridium difficile infection in the general hospital population: a systematic review","volume":"82","author":"Bloomfield","year":"2012","journal-title":"J Hosp Infect"},{"key":"2020082200570245300_CIT0031","doi-asserted-by":"crossref","first-page":"ofu045","DOI":"10.1093\/ofid\/ofu045","article-title":"Learning data-driven patient risk stratification models for Clostridium difficile","volume":"1","author":"Wiens","year":"2014","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz966\/30706107\/ciz966.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/5\/1133\/33671932\/ciz966.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/71\/5\/1133\/33671932\/ciz966.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T04:57:23Z","timestamp":1598072243000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/71\/5\/1133\/5574914"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":31,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,9,27]]},"published-print":{"date-parts":[[2020,8,22]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz966","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,9,1]]},"published":{"date-parts":[[2019,9,27]]}}}